Please assess the completion status of the following clinical trial:

Trial Title: A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Men and women age 18 and older~* 6-36 months after kidney transplant receiving cyclosporine or tacrolimus~* calculated GFR ≥35 and ≤75mL/min/1.73 m²~* subjects must have completed 1 year in the IM103-010ST and remained on study treatment (Long Term Extension)~Key Exclusion Criteria:~* Significant infection~* acute rejection within 3 months~* prior graft loss due to rejection~* pregnancy~* positive crossmatch

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Belatacept (Type: EXPERIMENTAL): None
- B: calcineurin inhibitor (CNI)-based immunosuppressive regimen (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).